LIXTE updates LB-100 clinical progress; two new trials started, $1.05M offering completed

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

First patient dosed in Phase 1b/2 trial combining LB-100 with GSK's dostarlimab for ovarian clear cell carcinoma.
First patient dosed in colorectal trial at Netherlands Cancer Institute supported by Roche for MSI Low metastatic CRC.
Received Notice of Allowance from USPTO for patent combining LB-100 with immunotherapies; also exclusive license agreement with NIH.
Completed registered direct offering raising $1.05M for working capital and general corporate purposes.
Two publications in Cancer Discovery and EMBO support LB-100's mechanism to force cancer cells to become vulnerable to immunotherapy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.